Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is well positioned to benefit from the ongoing paradigm shift towards value-based care, as its integrated consultative, IT, and health plan capabilities give it a competitive advantage in this space. With the divestment of its managed care businesses, Evolent is now solely focused on its high-growth services segment, which includes specialty care management services and an integrated platform for health plan administration. In addition, the company's strong financial outlook, with est. 2026/2027 adjusted EBITDA of $129M/$151M, and potential new contracts with downside protection, make Evolent a compelling investment opportunity in the healthcare delivery and payment sector.

Bears say

Evolent Health is expected to experience increasing unadjusted medical expense and declining trends, but with recent favorable claims performance, the company's rating and price target for high profitability remain Buy and USD $6, respectively.

Evolent Health (EVH) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 13 analysts, Evolent Health (EVH) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.